Ascendis considers selling entire biosciences division
Ascendis has also been in talks about a possible sale of its Remedica business in Cyprus, which is seen as key to reducing Ascendis’s debt
31 July 2019 - 12:50
Ascendis Health, whose shares have slumped on concerns about its debt levels and weak organic growth, says it is considering selling the two remaining businesses in its biosciences division after it offloaded three companies in that unit.
The sale of Afrikelp, Efekto and Marltons, announced in May, is now complete after receiving approval from competition authorities, Ascendis said on Wednesday. The businesses were sold to a consortium comprising RMB Ventures Seven, Nedbank Private Equity and some managers at Ascendis’s biosciences division. ..
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.